Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Organ-on-a-Chip & Tissue-on-a-Chip Europe 2019

Jan Lichtenberg's Biography



Jan Lichtenberg, CEO and Co-Founder, InSphero AG

Jan Lichtenberg, Ph.D., is Co-Founder and CEO of Swiss- and US-based InSphero Inc., the largest biotech specialized in 3D cell-culture technologies for discovery and safety. InSphero’s patented assay-ready 3D microtissues mimic the structure and functionality of organ tissue, e.g. liver, pancreas, or tumors including disease states like diabetes or NASH. The 3D microtissues allow for more predictive and reliable compound profiling for discovery and safety testing in a highly robust, rapid and cost-efficient way.

Jan co-founded InSphero in 2009 and grew the company to 65 employees in Switzerland and the US while expanding the business to encompass all top 15 global pharmaceutical companies. Prior to InSphero, Jan had VP R&D and Product Management positions at Hocoma AG (medical robotics) and Uwatec (microelectronics). He holds a Ph.D. from the University of Neuchâtel and managed a research group at the Swiss Federal Institute of Technology (ETH), Zurich. Since 2021 he is a Board Member of the Society of Laboratory Science and Screening (SLAS).

Jan Lichtenberg Image

Going 3D All The Way: 3D Microtissues in Modular Organ-on-a-Chip Solutions For Human-Centric Drug Discovery

Wednesday, 19 June 2019 at 11:00

Add to Calendar ▼2019-06-19 11:00:002019-06-19 12:00:00Europe/LondonGoing 3D All The Way: 3D Microtissues in Modular Organ-on-a-Chip Solutions For Human-Centric Drug DiscoveryOrgan-on-a-Chip and Tissue-on-a-Chip Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com

Scaffold-free 3D microtissues have evolved into the most widely used technology for highly predictive and most scalable cell-based assays in drug safety and discovery. While they provide a faithful in-vitro approximation of the in-vivo tissue microenvironment, they were not amenable for modeling microphysiological features up to now. Here, we present a new multi-organ-on-a-chip system featuring microfluidic channels and chambers that were specifically engineered for culturing 3D microtissues and organoids under physiological flow conditions. The platform complies with the SBS plate standard and is made of polystyrene to prevent unwanted compound absorption. It allows for an automated and on-demand interconnection of up to 10 microtissues per channel in a highly  flexible fashion. Different from the majority of organ-on-a-chip solutions, the off-chip formation of 3D microtissues allows for an optimized tissue engineering processes, pre-loading quality control and higher yields. Enabling an automated removal and re-insertion of 3D microtissues from and into the device, this platform finally ads deep endpoints such as next-gen sequencing, lipidomics, FACS to the analytical toolbox for organ-on-a-chip applications. We’ll illustrate this new approach with examples in DMPK for low clearance and microtissue cross talk.


Add to Calendar ▼2019-06-18 00:00:002019-06-19 00:00:00Europe/LondonOrgan-on-a-Chip and Tissue-on-a-Chip Europe 2019Organ-on-a-Chip and Tissue-on-a-Chip Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com